Calcium sulfanilamide preparations



Patented Oct. 7, 19 52 s PATENT oFFicE Simon L. Ruskin, New York, N. YQossignor to. Physiological. Chemicals Company, New Rochelle, N. Y., a corporationpf New York o oo STA-rs No Drawing; "Application March 2,1944,-

Serial No. 524,781;

The present invention relates to therapeutic preparations forthe'treatment of various upper respiratory infections, and more particularly to preparations-ofthis kind having both a bacteri- 15 Claims c1; ion-51 ,5)

2 ment of upper respiratory infections. I have, however, found that the calcium salts of the sulianilamides are sufficiently soluble in water to exert a strong bactericidal action, while being cidal and vasco-constricting action. at the same time substantially free from any More specifically the invention relates to irritating action on the sensitive membranes of preparations containing a calcium salt of a sulthe upper respiratory passages; and further, that fanilamide together with a vaso constrictor and where solutions of such calcium compounds with adapted'for-use, as by spraying. on-the mucosa of a vaso constrictor are unstable and tend to prethe upper respiratorychannels. v cipitate, they can be rendered stable for indefi- The present application is a. .continuation-innite periods in a simple and inexpensive manner. part of my copending application Serial No. According to the invention, therefore, stable 498,590, filed August 13, 1943. and non-caustic solutions having an adequate The desirability of employing a bactericide bactericidal and vaso constricting action are prealong with a vaso constrictor for application to pared by the use of the calcium salts of the sulfa the passages ofthe upper respiratory tract has drug such as. the calcium Compounds of S111- already been recognized. Sulfanilamide and its fanilamide, sulfathiazele, ulfad a and 111- various N -cyclic substituted derivatives do not amera e. together h a Vase constrictor, lend themselves for use as the bactericide in preierably desoxyephedrine. Solutions of this such a composition because of their low solu-. ype. as I h ve f u d. earl be ely used n the bility or insolubility in water. On the other nasal and th at passa s wit ut irritation and hand, the sodium salts of the sulfanilamides, wi h ut dan er Of Sl h 0f the delicate while they possess the necessary water-solubility, membranes, have the serious disadvantage that they are q u Solutions containing 1 or 2% f h quite caustic and strongly irritate the delicate calcium Sulfa Compound and a Smaller q y mucous membranes of the nose and throat pas- 0f desoxyeph r f r mple, 0.1 to 0.2% c sages. Sulf anilamide and its organically subd ly b pr p r in accordance w th t stitute d derivatives, and the sodium compounds Present invention which have a D Value 110 of these substances therefore represent unsatishigher than about and essentially o g e factory bactericides for use on sensitive mucous tmm which Solu ns re n -irrita in even membranes eith r b a of th i very l w' to delicate membranes. These small amounts of ter solubility, or because of their irritating action. calcium S l pou and a v n rietor It is the primary object of the invention to are ci t to p u e adequate antisep nd provide m di a t for use i t upper vaso-constriction so that a rapid healing action respiratory passages whichpossesses a vaso con- 5 is i l- Where the Solutions are freshly stricting and at the same time a strong bacteriode un h y can be u W ut further modicidal action, but substantially free from irritatfl i I have, however, fellnd at, for eX- ing or painful effects on sensitive tissues. mp e Solutions of calcium sulfathiazole and de- It is also an object .of the invention to provide 'soxyephedrine tend o precipitate n tanding a composition of the type indicated which is 40 longer than about we In afurther v stable over longperiods of time, and thus retains I h invention, these olutions are renits vaso constrictor and bactericidal action quite dered. stable Over indefinite periods y t e adindefinitely. Other objects of the invention will di'tion thereof of small quantities f relatively appear as the more detailed description of the highly q l C lcium salts, like calcium chloinvention proceeds ride orjbromide.- The amount necessary to ef- The calcium compounds of the sulfanilamides feet i i y is ex reme m Several hunare of relatively low solubility in water and such r hs 0f 1% being us lly Suflieient. The calfact, together with the known fact that calcium Ilium halogenides, in addition to stabilizing this compounds of complex organic substances are solution are of further advantage by reason of frequently if not usually unstable in aqueous the fact that they are themselves acidic in charsolution, especially when such solutions contain acter, so that they tend to reduce the basicity also other complex organic substances, would of the calcium sulfa drug solution. In place of appear to mark such calcium compounds'as'unthe calcium halogenides, calcium saccharate or suitable for use in an aqueous spray, together other soluble organic calcium salt may be emwith an organic vaso constrictor, for the treatployed; if desired, dextrose in an amount corresponding to about of the solution may be used. None of these stabilizing agents, it will be noted, reacts with the calcium sulfa drug to form an insoluble compound.

The following example illustrates a satisfactory manner of compounding the therapeutic agent in accordance with the invention. It will be understood that the proportions given are illustrative only and may be varied without departing from the spirit of the invention:

Twenty grams of calcium sulfathianole are stirred in a liter of distilled water until a clear solution is obtained. To this solution is added 0.33 gram of calcium chloride. One gram of desoxyephedrine solution is now added and the entire solution stirred for five minutes. The re- 11. A composition as defined in claim 10 wherein the calcium compound is calcium sulfathiazole.

12. A stable therapeutic composition suitable for application to the respiratory passages and comprising an aqueous solution containing about 1 to 5% of a calcium compound of a sulfanilamide,

about 0.1 to 0.2% of desoxyephedrine and about 0.03 to'1% of calcium chloride, said solution having a pH value in the alkaline range but no higher than 8.0, the quantity of calcium chloride being less than that of the sulfanilamide.

13. A therapeutic composition suitable for application .to the respiratory passages and comprising an aqueous solution containing a calcium compound of a sulfanilamide, desoxyephedrine v bsae, and calcium chloride, said solution having sultant solution is ready for use, and may be stored in well stoppered bottles. The solution is preferably applied in the form of a spray in the nasal and throat passages.

In similar fashion solutions of calcium sulfanilamide, calcium sulfadiazine and calcium sulfamarazine with suitable amounts of desoxy ephedrine or other compatible vaso constrictor may be prepared, with or without one of the stabilizing agents referred to above.

Among the other vaso constrictors that can be employed are ephedrine base or adrenaline base, in the amount of about 0.1%.

Other vaso constrictors not incompatible with the calcium sulfa drug solution can likewise be used.

I claim:

1. A therapeutic composition comprising. "an aqueous solution containing a calcium compound of a sulfanilamide, desoxyephedrine, and an efiective quantity but less than 1% of calcium chloride as a stabilizing agent;

2. A composition as defined in claim 1 where the calcium compound is calcium sulfanilamide.

3. A composition as defined in claim 1 wherein the calcium compound is calcium sulfathiazole.

4. A composition as defined in claim 1 wherein the calcium compound is a calcium sulfapyrimidine. I

5. A composition as defined in claim 1 wherein the calcium compound is calcium sulfadiazene.

6. A therapeutic composition suitable for application to the respiratory passages'and containing a calcium compound of a sulfanilamide having an anti-bacterial action, desoxyephedrine base, and a small proportion of calciumchloride.

7. A therapeutic composition containing a calcium compound of a sulfanilamide having an anti-bacterial action, together with calcium chloride as a stabilizing agent, all in aqueous solution.

8. A therapentic composition containing a calcium compound of sulfathiazole, together with a small proportion of calcium chloride as a stabilizing agent, all in aqueous solution.

9. A therapeutic composition suitable for application to the respiratory passages and containing a calcium compound of a sulfanilamide having an anti-bacterial action, a member of the group consisting of desoxyephedrine, ephedrine and adrenaline, and a small proportion of calcium chloride.

10. A therapeutic composition comprising an aqueous solution containing a calcium compound of a sulfanilamide having an anti-bacterial action, a member of the group consisting of desoxyephedrine, ephedrine andadrenaline, and andfective quantity but less than one percent of calcium chloride as a stabilizing agent.

'a pH value in the alkaline range but no higher than 8.0, the quantity of calcium chloride being less than "that of the sulfanilamide.

14. A therapeutic composition comprising an aqueous solution of a calcium compound of a sulfanilamidehaving an anti-bacterial action. desoxyephedrine base, and as a stabilizer, a highly soluble calcium salt, said solution having a pH value in the alkaline range but no higher than 8.0, the quantity of calcium chloride being less than that of the sulfanilamide.

15. A therapeutic composition suitable for application to therespiratory passages and comprising an aqueous solution of a calcium compound of a sulfanilamide having an anti-bacterial actiomdesoxyephedrine base, and as a stabilizer, a calcium halogenide, said solution having a pH value in the alkaline range but no higher than 8.0, the quantity of calcium halogenide being less than thatof the sulfanilamide.

, V SIMON L. RUSKIN.

' REFERENCES CITED The following references are of record in the file of this patent:

' UNITED STATES PATENTS Number Name Date 1,965,535 Pasternack July 3, 1934 2,252,822 Vogenthaler Aug. 19, 1941 2,265,453 Schmidt Dec. 9, 1941 2,325,029 Baker July 24, 1943 2,361,624 Hamilton Oct. 31, 1944 2,369,711 Blythe Feb. 20, 1945 2,389,582 Winnek Nov. 20, 1945 2,396,711 I Lott Mar. 19, 1946 FOREIGN PATENTS Number Country Date 111,230 Australia 1939 114,894 Australia Mar. 17, 1942 213,815 Switzerland June 3, 1941 683,866 Germany Nov. 17, 1939 839,711 France Jan. 7, 1939 OTHER REFERENCES Jenkins: Journ. Amer. Phar. Assn. June 1938,

vol. 27, pp. 484 -487.

U. S Dispensatory,.23d edition (1943), pages 230 and 231, 

1. A THERAPEUTIC COMPOSITION COMPRISING AN AQUEOUS SOLUTION CONTAINING A CALCIUM COMPOUND OF A SULFANILAMIDE, DESOXYEPHEDRINE, AND AN EFFECTIVE QUANTITY BUT LESS THAN 1% OF CALCIUM CHLORIDE AS A STABILIZING AGENT. 